Tests cemsidomide with elranatamab in adults with relapsed or refractory multiple myeloma
Tests cemsidomide plus elranatamab, to learn safety, in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Key facts
- Where
- Atlanta, Baltimore, Brooklyn, Columbus, Dallas, Durham, Gilbert, Grand Rapids, Houston, Indianapolis, Lebanon, Louisville, Maywood, Miami, New York, Omaha, Sacramento, Salt Lake City, and Santa Monica, United StatesSee the 19 sites
- Phase
- Phase 1
Where in United States
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesTaking people
- University of Maryland Greenbaum Comprehensive Cancer CenterBaltimore, United StatesTaking people
- Perlmutter Cancer Center at NYU Langone HospitalBrooklyn, United StatesTaking people
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesNot yet recruiting
- Baylor University Medical CenterDallas, United StatesNot yet recruiting
- Duke Cancer CenterDurham, United StatesTaking people
- Banner MD Anderson Cancer CenterGilbert, United StatesTaking people
- START | MidwestGrand Rapids, United StatesTaking people
- Houston Methodist HospitalHouston, United StatesTaking people
- Indiana UniversityIndianapolis, United StatesNot yet recruiting
- Dartmouth Hitchcock Medical CenterLebanon, United StatesTaking people
- Norton Cancer Institute St. MatthewsLouisville, United StatesTaking people
- Loyola University Medical CenterMaywood, United StatesNot yet recruiting
- University of MiamiMiami, United StatesNot yet recruiting
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- University of NebraskaOmaha, United StatesNot yet recruiting
- UC Davis Comprehensive Cancer CenterSacramento, United StatesTaking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesNot yet recruiting
- UCLA Health, Jonsson Comprehensive Cancer CenterSanta Monica, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- C4 Therapeutics, Inc.
- Trial code
- NCT07280013
- Record updated
- 30 October 2026
- Original description
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.Read full original descriptionShow less
A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.
The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity.
Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.
Inclusion: Diagnosis of multiple myeloma as defined by IMWG criteria; Measurable disease based on IMWG criteria; Received 2-4 prior lines of therapy (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader); ECOG performance status 0-2.
Exclusion: Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease; Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy; Administration with an investigational product within 30 days preceding the first dose of study intervention; Active plasma cell leukemia, Smoldering multiple myeloma, POEMS Syndrome, systemic light chain amyloidosis, MDS; Participants with any active, uncontrolled bacterial, fungal, or viral infection; Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function.